ProCE Banner Activity


BTK Inhibitor Therapy for Patients With CLL: A Global Perspective

Text Module

In this text-based activity, an international expert discusses best practices in the use of BTK inhibitors for patients with CLL, including AE management and treatment recommendations.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 13, 2023

Expiration: March 12, 2024

No longer available for credit.



Toby A. Eyre

Toby A. Eyre, MBChB, MD

Hematology Consultant at Oxford University Hospitals
Senior Lecturer at the University of Oxford
Oxford, United Kingdom

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from AstraZeneca.


Target Audience

This program is intended for global hematologists, medical oncologists, and other healthcare professionals involved in treatment of patients with CLL.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of global learners to apply practice-changing clinical data and expert recommendations to optimize the use of current and emerging therapeutic strategies with BTK inhibitors in the care of their patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the approved BTK inhibitors considering binding, targeted selectivity, global indications, dosing, safety profile, and efficacy

  • Plan BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL taking into consideration global indications, expert recommendations, and recent practice-changing clinical trial results

  • Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation for optimal patient outcomes


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Toby A. Eyre, MBChB, MD

Hematology Consultant at Oxford University Hospitals
Senior Lecturer at the University of Oxford
Oxford, United Kingdom

Toby Eyre, MBChB, MD: advisor: AbbVie, AstraZeneca, Incyte, Janssen, Kite/Gilead, Loxo, Lilly, Roche.

The planners and content peer reviewers from Clinical Care Options, LLC do not have an relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 13, 2023, through March 12, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.